2025年5月27日，意领科技FattaLab®新品发布暨“创新应用场景孵化平台”及大中华区“ELT+肝筛联盟”揭榜活动圆满举办，意领科技重磅推出了脂肪肝检测革新力作——FattaLab®，现场邀请了众多业界知名专家领导、合作伙伴、投资方等共聚香港科学园，一同见证意领科技在肝脏健康检测领域的里程碑时刻。
创新探索：脂肪肝检测技术的全新突破
Before the new product launch, Eieling Technology CEO Jia Xiaojia delivered an opening speech, first expressing his sincere gratitude to the leaders at all levels and strategic partners present, and emphasized that Eieling Technology will continue to promote product iteration and upgrades, break through existing technological barriers with technological innovation, and benefit more liver disease patients.
CEO|Co-Founder of Eieling Xiaojia JIA
Mr Eric Or, Acting Chief Corporate Development Officer, Hong Kong Science & Technology Parks Corporation
In the Annual Review of the “Hong Kong LiverCare Project”, Zihao HUANG, PhD, Chief Research Officer of EIELING, systematically sorted out six typical screening scenarios in Hong Kong and presented them through multi-dimensional data, demonstrating Eieling’ technological leadership and social service value in large-scale grassroots early screening of liver disease.
Zihao HUANG, PhD, Chief Research Officer of EIELING
FattaLab®新品发布环节，意领科技产品总监姜天宇从多角度对新品的亮点进行了专业解读，全面展示了新品在技术突破、重量、外观、检测效率、应用前景等方面的升级和应用价值。
意领科技产品总监姜天宇
Afterwards, in the Unveiling Ceremony of The FattaLab® New Product Experience Officer, Professor Zheng Yongping, Chair Professor of Biomedical Engineering, The Hong Kong Polytechnic University, and Mr. Xiaojia JIA, CEO|Co-Founder of Eieling, jointly presented new products to the first batch of “New Product Experience Officers”.
香港理工大学生物医学工程讲座教授郑永平教授
香港理工大学副校长（研究及创新）赵汝恒教授
香港大学医学院玛丽医院胃肠肝脏科司徒伟基教授
香港贸易发展局副总裁刘会平先生
广州多浦乐电子科技股份有限公司董事长蔡庆生先生
从左至右依次为意领科技CEO贾晓嘉先生、广州多浦乐电子科技股份有限公司董事长蔡庆生先生、金来囯际有限公司董事总经理香港理工大学上海校友会会长钟耀光先生、香港理工大学副校长（研究及创新）赵汝恒教授、香港大学医学院玛丽医院胃肠肝脏科司徒伟基教授、香港贸易发展局副总裁刘会平先生、香港贸易发展局中国内地总代表钟永喜先生、意领投资人郑衡岳先生、香港理工大学知识转移与创新处总监王家达先生、香港理工大学生物医学工程讲座教授郑永平教授
在FattaLab®新品发布现场同步举行了两场战略级合作签约仪式，此次合作意义非凡，各方秉持着“让精准检测触达每一位国民”的信念，为消除肝病危害付诸行动，为国民肝脏健康筑牢坚实防线。
欧艾赛特生物科技有限公司CEO潘辉先生（左）
意领科技CEO贾晓嘉先生（右）
广州友保健康科技有限公司CEO尹华先生（左）
意领科技CEO贾晓嘉先生（右）
在大中华区“ELT+肝筛联盟”揭榜发布环节，每位专家都对我国脂肪肝防控严峻形势展开深度探讨，并强调肝脏早筛是阻断肝病恶化的“第一道防线”。联盟成员将共同推动筛查技术的下沉，携手同行，践行“健康中国”的使命！
From left to right: CEO|Co-Founder of Eieling Xiaojia JIA、Dr. Wu Guoyi， Researcher, Shanghai Public Health Clinical Center, Fudan University、Prof. Zheng Qiuying， Director of the Department of Health and Pharmaceutical Industry, Beijing University of Chinese Medicine、Mr. Li Mingyang，Director of China Liver Health (CLH)、Prof. Wai-Kay Seto， Department of Gastroenterology & Hepatology, Queen Mary Hospital, The University of Hong Kong、Prof. Li Bo， Department of Hepatobiliary Surgery, Affiliated Hospital of Southwest Medical University、Prof. Lin Xuan， Department of Endocrinology, Nutrition, and Weight Management, CR & WISCO General Hospital、Prof. Zheng Yongping， Chair Professor of Biomedical Engineering, The Hong Kong Polytechnic University
肝病早筛的技术边界与应用范式的重新定义
本次发布的全球首款轻量化脂肪肝智能评估系统FattaLab®实现了从“估算”到“诊断级”的技术突破，堪称行业的里程碑式的产品。FattaLab®集轻量化、便携化、个性化为一体，30秒即可完成肝脏数据采集，一键启停自动分析，并通过移动端APP实时输出报告，检测、干预、保障全链路管理，重量减轻至140g，是唯一实现‘医疗级精度+准家用级场景+闭环式服务’的产品，FattaLab®无疑重新定义了肝病早筛的技术边界与应用范式。
脂肪肝全球患者超30亿，有80%的患者在早期毫无症状。我国慢性肝病患者超2亿，肥胖/糖尿病高危人群肝纤维化筛查率不足 15%。脂肪肝已经成为困扰众多群众的问题。FattaLab®的出现，有望推动肝脏健康检测成为像血压计、体温计一样的家庭健康刚需设备。
The successful launch of ElELING FattaLab® New Product Launch and the unveiling ceremony of “Innovative Application Scenario Incubation Platform” and the “ELT+ Liver Screening Alliance” in the Greater China highlight the innovative strength of FattaLab in precision medicine for liver diseases. In the future, Eieling will continue to deepen its technology and work with all parties to jointly promote the iterative upgrade of liver testing technology towards “non-invasive, accurate, and inclusive”, so that the concept of “early screening, early diagnosis, and early treatment” can be truly implemented.